重启后首家获受理，高瓴入股

Group 1 - The core point of the news is that Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has had its IPO application accepted by the Shanghai Stock Exchange, marking the first company to be accepted under the newly restarted fifth set of listing standards on the Sci-Tech Innovation Board [1][3] - Tainuo Maibo is the first company to apply the qualified institutional investor system, with Hillhouse Capital having held 3.94% of the company's shares for 24 months prior to the IPO application [3][4] - Founded in 2015, Tainuo Maibo is an innovative biopharmaceutical company, with its core product, Staidotamab Injection (New Timo®), approved for market in February 2025, recognized as the first domestic innovative monoclonal antibody drug for tetanus [3][4] Group 2 - The company has reported continuous net losses from 2022 to 2025, with a cumulative unabsorbed loss of 1.024 billion yuan as of March 2025 [3] - The introduction of the qualified institutional investor system is seen as a practical implementation of the "1+6" new policy, enhancing the role of the Sci-Tech Innovation Board in serving unprofitable tech companies [3][5] - The qualified institutional investor system is a mature practice in overseas markets, aimed at leveraging the expertise of top venture capital and industry funds to provide market insights during the review process [4][5]